Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.

Dick P, Grandjean ME, Tissot R

Neuropsychobiology1 Jan 1983Cited by 9 (Europe PMC)

PMID6328354DOI10.1159/000118012PepBankPUB-06328354

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialSafety outcome
In 67 patients with withdrawal symptoms, no major side-effect occurred after intravenous DSIP.
In plain wordsIn people given DSIP for withdrawal symptoms, no major side-effect occurred. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeMajor side-effects
Study
n = 67
Outcome group
Adverse events · Whole body
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Source sentences
Summary
No major side-effect occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835406
02HumanNon-randomized trialEfficacy outcome
In 49 evaluable patients with alcohol or opiate withdrawal, intravenous DSIP given as sole treatment produced a beneficial effect in 48.
In plain wordsIn people withdrawing from alcohol or opiates, DSIP gave a benefit in 48 of 49 evaluable patients. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseBeneficial effect on withdrawal symptoms
Study
n = 49
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Measurements
Patients with beneficial effect
48 patients
49 evaluable patients
Source sentences
Summary
From the 49 evaluable patients, DSIP produced a beneficial effect in 48 (22 alcoholics and 26 from 27 opiate addicts), with an immediate onset of action, a good and lasting suspension of the somatic symptoms and signs.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835401
03HumanNon-randomized trialEfficacy outcome
In evaluable patients with withdrawal, DSIP had an immediate onset of action and a good and lasting suspension of somatic symptoms and signs.
In plain wordsIn people withdrawing from alcohol or opiates, DSIP quickly eased body symptoms and signs, and the effect lasted. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseSomatic withdrawal signs and symptoms
Study
n = 49
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Source sentences
Summary
with an immediate onset of action, a good and lasting suspension of the somatic symptoms and signs.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835404
04HumanNon-randomized trialEfficacy outcome
In opiate addicts with withdrawal symptoms, DSIP produced a beneficial effect in 26 of 27 patients.
In plain wordsIn people withdrawing from opiates, DSIP gave a benefit in 26 of 27 patients. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseBeneficial effect in opiate withdrawal
Study
n = 27
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Measurements
Patients with beneficial effect
26 patients
opiate addicts
Source sentences
Summary
26 from 27 opiate addicts
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835403
05HumanNon-randomized trialEfficacy outcome
In patients with ethyl alcohol withdrawal, DSIP produced a beneficial effect in 22 patients.
In plain wordsIn people withdrawing from alcohol, DSIP gave a benefit in 22 patients. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseBeneficial effect in alcohol withdrawal
Study
n: not reported in source
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Measurements
Patients with beneficial effect
22 patients
alcoholics
Source sentences
Summary
DSIP produced a beneficial effect in 48 (22 alcoholics
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835402
06HumanNon-randomized trialEfficacy outcome
In patients with withdrawal symptoms treated with DSIP, anxiety resolved more slowly, within hours.
In plain wordsIn people withdrawing from alcohol or opiates given DSIP, anxiety went away more slowly, within hours. There was no control group.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseAnxiety resolution
Study
n: not reported in source
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
25 nmol/kg · intravenousAs given in this study (human).
Source sentences
Summary
Anxiety resolved more slowly, within hours.
1 context sentence(design, population, supporting numbers)
Summary · context
To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates).
Report a problemFND-0632835405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.